Kiri A Sandler1, Narek Shaverdian1, Ryan R Cook2, Amar U Kishan1, Christopher R King1, Isaac Yang3,4, Michael L Steinberg1,3, Percy Lee1,3. 1. Department of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 2. Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California. 3. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 4. Department of Neurosurgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: Published guidelines regarding the optimal treatment strategies for brain metastases focus on patients with ≤3 lesions. As delivery techniques for stereotactic radiosurgery (SRS) improve, radiation oncologists are increasingly using it for patients with >3 metastases. In the current study, the authors sought to characterize practice patterns among practitioners to identify areas of controversy. METHODS: A survey of practicing radiation oncologists was distributed via e-mail. Responses were collected from April 1 to May 5, 2016. Survey data were analyzed. RESULTS: A total of 711 currently practicing radiation oncologists responded, for a response rate of 12.5%. Specialists in central nervous system tumors (CNS specialists) were more likely to treat higher numbers of patients with brain metastases with SRS. There was a significant difference in the optimal "cutoff number" used when deciding how many lesions to treat with SRS versus whole-brain radiotherapy. Cutoff numbers were significantly higher for high-volume CNS specialists (≥10 patients/month) than for either low-volume CNS specialists (5-9 patients/month) or high-volume, non-CNS specialists (8.1 vs 5.6 and 5.1, respectively; P<.001). A majority of respondents (56%) identified patients with 4 to 6 brain metastases as being the most challenging patients to treat. CONCLUSIONS: To the authors' knowledge, there appears to be no consensus regarding the optimal treatment strategy among patients with >3 brain metastases, and practice patterns are heterogeneous. Radiation oncologists, especially high-volume CNS specialists, are treating significantly more brain metastases with SRS than what currently is recommended by published consensus guidelines. Providers struggle with patients with a moderate intracranial disease burden. Further prospective studies are needed to support these practice patterns and guide decision making. Cancer 2017;123:2274-2282.
BACKGROUND: Published guidelines regarding the optimal treatment strategies for brain metastases focus on patients with ≤3 lesions. As delivery techniques for stereotactic radiosurgery (SRS) improve, radiation oncologists are increasingly using it for patients with >3 metastases. In the current study, the authors sought to characterize practice patterns among practitioners to identify areas of controversy. METHODS: A survey of practicing radiation oncologists was distributed via e-mail. Responses were collected from April 1 to May 5, 2016. Survey data were analyzed. RESULTS: A total of 711 currently practicing radiation oncologists responded, for a response rate of 12.5%. Specialists in central nervous system tumors (CNS specialists) were more likely to treat higher numbers of patients with brain metastases with SRS. There was a significant difference in the optimal "cutoff number" used when deciding how many lesions to treat with SRS versus whole-brain radiotherapy. Cutoff numbers were significantly higher for high-volume CNS specialists (≥10 patients/month) than for either low-volume CNS specialists (5-9 patients/month) or high-volume, non-CNS specialists (8.1 vs 5.6 and 5.1, respectively; P<.001). A majority of respondents (56%) identified patients with 4 to 6 brain metastases as being the most challenging patients to treat. CONCLUSIONS: To the authors' knowledge, there appears to be no consensus regarding the optimal treatment strategy among patients with >3 brain metastases, and practice patterns are heterogeneous. Radiation oncologists, especially high-volume CNS specialists, are treating significantly more brain metastases with SRS than what currently is recommended by published consensus guidelines. Providers struggle with patients with a moderate intracranial disease burden. Further prospective studies are needed to support these practice patterns and guide decision making. Cancer 2017;123:2274-2282.
Authors: Carmine Antonio Donofrio; Andrea Cavalli; Marco Gemma; Lucia Riccio; Alessandra Donofrio; Pietro Panni; Camillo Ferrari da Passano; Antonella Del Vecchio; Angelo Bolognesi; Riccardo Soffietti; Pietro Mortini Journal: Clin Exp Metastasis Date: 2020-05-19 Impact factor: 5.150
Authors: Kyle Wang; Kevin A Pearlstein; Dominic H Moon; Zahra M Mahbooba; Allison M Deal; Yue Wang; Stephanie R Sutton; Britni B Motley; Gregory D Judy; Jordan A Holmes; Nathan C Sheets; Mohit S Kasibhatla; Heather D Pacholke; Colette J Shen; Timothy M Zagar; Lawrence B Marks; Bhishamjit S Chera Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Erik Scott Blomain; Hyun Kim; Shivank Garg; Deepak Bhamidipati; Jenny Guo; Ingrid Kalchman; John McAna; Wenyin Shi Journal: J Radiat Oncol Date: 2018-05-11
Authors: David M Routman; Shelly X Bian; Kevin Diao; Jonathan L Liu; Cheng Yu; Jason Ye; Gabriel Zada; Eric L Chang Journal: Cancer Med Date: 2018-02-14 Impact factor: 4.452
Authors: Jianling Yuan; Richard Lee; Kathryn Ellen Dusenbery; Chung K Lee; Damien C Mathew; Paul Wayne Sperduto; Yoichi Watanabe Journal: Front Oncol Date: 2018-03-13 Impact factor: 6.244
Authors: Yuanxuan Xia; Leila A Mashouf; Brock R Baker; Russell Maxwell; Chetan Bettegowda; Kristin J Redmond; Lawrence R Kleinberg; Michael Lim Journal: Cureus Date: 2018-07-30